Os destaques do programa científico do San Antonio Breast Cancer Symposium (SABCS 2022) e seu impacto na prática clínica estão em foco no PODCAST ONCONEWS, com apresentação de Silvio Bromberg e Daniel Gimenes. Nesta edição os especialistas recebem Karla Kabbach, patologista do Hospital Israelita Albert Einstein e docente na Universidade Federal de São Paulo (Unifesp), que discute trabalhos que avaliam o status HER2-low e a expressão Ki67 no câncer de mama. Confira.

Referências:

1. Abstract GS1-10 - Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy - Yen-Shen Lu et al

2. Abstract GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer - Presenting Author: Aditya Bardia et al

3. Abstract GS4-09 - Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13) - Ann Partridge et al

4. Abstract GS4-01 - Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from ACOSOG Z11102 (Alliance) - Judy C. Boughey et al

5. GS4-02 Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study - Giacomo Montagna

6. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.

7. Schettini, F., Chic, N., Brasó-Maristany, F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer 7, 1 (2021). https://doi.org/10.1038/s41523-020-00208-2

8. Robbins C, Fernandez A, Han G, et al. Multi-institutional Assessment of Pathologist scoring HER2 Immunohistochemistry. Research Square; 2022. DOI: 10.21203/rs.3.rs-1763087/v1.

9. Moutafi, M., Robbins, C.J., Yaghoobi, V. et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest 102, 1101–1108 (2022). https://doi.org/10.1038/s41374-022-00804-9

10. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 Jul 1;113(7):808-819. doi: 10.1093/jnci/djaa201.

11. Rimm, D.L., Leung, S.C.Y., McShane, L.M. et al. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod Pathol 32, 59–69 (2019). https://doi.org/10.1038/s41379-018-0109-4

12. Acs B, Pelekanou V, Bai Y, Martinez-Morilla S, Toki M, Leung SCY, Nielsen TO, Rimm DL. Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Lab Invest. 2019 Jan;99(1):107-117. doi: 10.1038/s41374-018-0123-7.

--

A perda de positividade HER2 após terapia-alvo neoadjuvante está associada a resultados oncológicos inferiores?

OnconewsBy onconewsSep 11, 2021